These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22267329)

  • 1. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis.
    Daïen CI; Duny Y; Barnetche T; Daurès JP; Combe B; Morel J
    Ann Rheum Dis; 2012 Jun; 71(6):862-8. PubMed ID: 22267329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies.
    Di Minno MN; Ambrosino P; Peluso R; Di Minno A; Lupoli R; Dentali F;
    Ann Med; 2014 Mar; 46(2):73-83. PubMed ID: 24460516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study.
    Hassan S; Milman U; Feld J; Eder L; Lavi I; Cohen S; Zisman D
    Arthritis Res Ther; 2016 Nov; 18(1):261. PubMed ID: 27832797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
    van Sijl AM; Peters MJ; Knol DL; de Vet RH; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
    Semin Arthritis Rheum; 2011 Dec; 41(3):393-400. PubMed ID: 21665247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in High-Density Lipoprotein Quantity and Quality Contribute to the Cardiovascular Benefits by Anti-tumor Necrosis Factor Therapies in Rheumatoid Arthritis: A Systemic Review and Meta-Analysis.
    Luo Y; Ren X; Weng S; Yan C; Mao Q; Peng D
    Front Cardiovasc Med; 2021; 8():765749. PubMed ID: 34778416
    [No Abstract]   [Full Text] [Related]  

  • 9. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
    Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP
    Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.
    Dessein PH; Stanwix AE; Joffe BI
    Arthritis Res; 2002; 4(5):R5. PubMed ID: 12223108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein.
    Rodríguez-Carrio J; Alperi-López M; López P; López-Mejías R; Alonso-Castro S; Abal F; Ballina-García FJ; González-Gay MÁ; Suárez A
    J Clin Lipidol; 2017; 11(4):1043-1054.e2. PubMed ID: 28662934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
    Toussirot É
    Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.
    Conti F; Atzeni F; Massaro L; Chiara Gerardi M; Gremese E; Passiu G; Carletto A; Malavolta N; Foti R; Ramonda R; Sarzi-Puttini P
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii11-vii22. PubMed ID: 30289537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
    Curtis JR; John A; Baser O
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR; Engstrand S; Berglin E; Johnson O
    Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Leporini C; Russo E; D Angelo S; Arturi F; Tripepi G; Peluso R; Grembiale RD; Olivieri I; De Sarro G; Ursini F
    Rev Recent Clin Trials; 2018; 13(3):184-191. PubMed ID: 29542420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.